+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy



A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy



American Journal of Hematology 89(6): 646-650



Iron deficiency anemia (IDA) is the most common form of anemia worldwide. Although oral iron is used as first-line treatment, many patients are unresponsive to or cannot take oral iron. This Phase III, open-label, non-inferiority study compared the efficacy and safety of ferumoxytol, a rapid, injectable intravenous (IV) iron product with low immunological reactivity and minimal detectable free iron, with IV iron sucrose in adults with IDA of any cause. Patients (N = 605) were randomized 2:1 to receive ferumoxytol (n = 406, two doses of 510 mg 5 ± 3 days apart) or iron sucrose (n = 199, five doses of 200 mg on five nonconsecutive days over 14 days) and followed for 5 weeks. Ferumoxytol demonstrated noninferiority to iron sucrose at the primary endpoint, the proportion of patients achieving a hemoglobin increase of ≥2 g dL(-1) at any time from Baseline to Week 5 (ferumoxytol, 84.0% [n = 406] vs. iron sucrose, 81.4% [n = 199]), with a noninferiority margin of 15%. Ferumoxytol was superior to iron sucrose (2.7 g dL(-1) vs. 2.4 g dL(-1) ) in the mean change in hemoglobin from Baseline to Week 5 (the alternative preplanned primary endpoint) with P = 0.0124. Transferrin saturation, quality-of-life measures, and safety outcomes were similar between the two treatment groups. Overall, ferumoxytol demonstrated comparable safety and efficacy to iron sucrose, suggesting that ferumoxytol may be a useful treatment option for patients with IDA in whom oral iron was unsatisfactory or could not be used.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051072343

Download citation: RISBibTeXText

PMID: 24639149

DOI: 10.1002/ajh.23712


Related references

Safety and efficacy of ferumoxytol for the episodic treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy: Results of a phase III, open-label, 6-month extension study. American Journal of Hematology 91(2): E3-E5, 2016

Tu1073 Evaluation of Ferumoxytol Treatment for Iron Deficiency Anemia in Patients With Gastrointestinal Disorders Who Have a History of Unsatisfactory Oral Iron Therapy: Results of a Phase Iii, Randomized, Placebo-Controlled Trial. Gastroenterology 144(5): S-754, 2013

Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study. American Journal of Gastroenterology 100(11): 2503-2509, 2005

Tu1743 Iv Iron Treatment of Iron Deficiency Anemia with Ferumoxytol in Patients with Inflammatory Bowel Disease Unable to Take Oral Iron: A Randomized Controlled Trial Versus Ferric Carboxymaltose. Gastroenterology 156(6): S-1107-S-1108, 2019

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. Nephrology Dialysis Transplantation 30(9): 1577-1589, 2015

Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial. Journal of Obstetrics and Gynaecology Research 39(2): 504-510, 2013

Treatment of iron-deficiency anemia with IV ferumoxytol in CKD patients: Efficacy compared with oral iron across different age groups. 2007

Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). Journal of Perinatal Medicine 45(4): 443-453, 2017

Ferumoxytol versus iron sucrose treatment: a post-hoc analysis of randomized controlled trials in patients with varying renal function and iron deficiency anemia. Bmc Hematology 16: 20, 2016

A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clinical Journal of the American Society of Nephrology 9(4): 705-712, 2014

Intravenous iron sucrose versus oral iron ferrous sulfate for antenatal and postpartum iron deficiency anemia: a randomized trial. Journal of Maternal-Fetal and Neonatal Medicine 26(7): 654-659, 2013

A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. American Journal of Hematology 92(3): 286-291, 2017

A randomised controlled trial to compare intravenous iron sucrose and oral iron in treatment of iron deficiency anemia in pregnancy. Indian Journal of Hematology and Blood Transfusion 30(2): 120-125, 2014

The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale. Bmc Nephrology 18(1): 117, 2017

Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents. Asia-Pacific Journal of Clinical Oncology 14(2): E129-E137, 2018